metaEvidence - overview


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mUC - L1 - all population metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - all population
mUC - L1 - PDL1 positive metastatic/advanced UC (mUC) - 1st Line (L1) mUC - L1 - PDL1 positive
mUC - L2 - all population metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - all population
mUC - L2 - PDL1 positive metastatic/advanced UC (mUC) - 2nd Line (L2) mUC - L2 - PDL1 positive
mUC - M - all population metastatic/advanced UC (mUC) - maintenance (M) mUC - M - all population
mUC - M - PDL1 positive metastatic/advanced UC (mUC) - maintenance (M) mUC - M - PDL1 positive
MIBC - NA - all population muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - all population
versus placebo
	nivolumab alone vs. placebo	1	-	-	-748 [-1482; -14] /10000 162/353 vs. 190/356
MIBC - NA - PDL1 positive muscular invasive bladder cancer (MIBC) MIBC - (neo)adjuvant (NA) MIBC - NA - PDL1 positive
versus placebo
	nivolumab alone vs. placebo	1	-	-	-1636 [-2785; -487] /10000 54/140 vs. 78/142